Nexalin Technology, a medical device company focused on non-invasive neurostimulation, has been awarded a United States patent for its novel method of delivering electrical pulses to the brain. The patent, confirmed by the company this week, covers a specific waveform and delivery system designed to treat conditions such as depression, anxiety, and chronic pain without the need for surgery or implants.
The patented method, known as transcranial electrical stimulation, uses a low-frequency current applied via electrodes on the scalp. Nexalin claims this approach can modulate brain activity more effectively than existing devices, potentially offering a safer alternative to pharmaceutical treatments. The company's shares saw a modest uptick in over-the-counter trading following the announcement.
For UK investors, the development signals a potential expansion opportunity for Nexalin in the European market. The company is already conducting clinical trials in the UK, with results expected later this year. Industry analysts note that neurostimulation is a rapidly growing sector, projected to be worth over £8 billion globally by 2030, driven by rising mental health awareness and the opioid crisis.
Dr Helen Forrester, a neuroscientist at King's College London, commented: 'This patent strengthens Nexalin's competitive edge. Non-invasive brain stimulation is gaining traction as a treatment for resistant depression, and a robust IP portfolio is crucial for attracting NHS contracts or private healthcare partnerships.' However, she cautioned that regulatory approval from the MHRA would be required before UK patients could access the therapy.
The news comes amid broader interest in brain-computer interfaces and neuromodulation. While Nexalin's technology is still in early stages, the patent provides a clear path to monetisation through licensing or direct sales. Investors should note that the company remains pre-revenue, with significant R&D costs ahead.